Long-lasting delivery of HIV prevention medications
Official title: Systemic Sustained Release Delivery of Antiretroviral Agents for HIV Prevention
Funded at Oak Crest Institute of Science · NIH-10854871 · Data updated 2026-11-12
This study is testing a new way to deliver HIV prevention medications that could make it easier for people to stay protected, with options for taking them less often, like once a month or even less frequently.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oak Crest Institute of Science NIH-funded |
| Lab location | 1 site (Monrovia, United States) |
| Project start | July 15, 2021 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $736,698 |
| NIH project number | 5R01AI162151-04 |
| Project ID | NIH-10854871 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at high risk of contracting HIV who may benefit from long-acting preventive treatments.
✕Less likely to help
Patients who are already HIV positive or those who do not have risk factors for HIV infection may not receive benefit from this research.
What this research studies
This research focuses on developing a new method for delivering antiretroviral medications to prevent HIV infection. By creating long-acting formulations that require less frequent dosing, the study aims to improve adherence to HIV prevention strategies. Patients will benefit from a more convenient and effective way to protect themselves from HIV, as the new delivery system could potentially allow for monthly or even less frequent dosing. The research involves clinical evaluations of these new formulations to ensure their safety and effectiveness.
Why it matters
Potential benefit: If successful, this research could provide a more effective and convenient method for HIV prevention, significantly reducing new infection rates.
How similar studies have gone: Previous research has shown success with long-acting formulations in other areas of medicine, indicating potential for similar advancements in HIV prevention.
Where this research is happening
-
Oak Crest Institute of Science
Monrovia, United States Active
Researchers
- Principal investigator: Baum, Marc Michael — Oak Crest Institute of Science
- Study coordinator: Baum, Marc Michael
Related research
Other NIH-funded projects on the same topics.
-
Making HIV prevention and care easier for Ugandan youth
A Ugandan study is testing ways to help adolescents and young adults (15–24) prevent HIV and stay healthy, using long-acting PrEP and youth-friendly services.
-
Innovative HIV Prevention and Care Interventions for Adolescents and Young Adults in Uganda
A Ugandan research team is testing practical, youth-focused strategies to help 15-24 year-olds using HIV prevention or treatment services stay healthy and engaged in care.
-
Adolescent girls in Uganda: a long-term look at how money empowerment and family support affect HIV prevention, care, and mental health
A long-term study in rural Uganda will test whether an intervention that combines economic empowerment and family strengthening can help HIV-negative and HIV-affected adolescent girls move safely into young adulthood.
-
Long-term HIV prevention and mental health support for adolescent girls and young women in Uganda
A long-term program in rural Uganda tests if combining economic support and family strengthening helps teenage girls stay HIV-free and improve mental health as they grow into young adults.
-
Harnessing male peer networks to boost HIV testing and PrEP use
A large clinical trial in South Africa tests whether giving HIV self-test kits through male peer networks, with phone support, increases PrEP uptake among men.
-
Harnessing men's peer networks to boost HIV self-testing and PrEP use
A large project in South Africa tests whether giving HIV self-test kits through men’s social networks, with phone support, can lead to more men starting PrEP and using HIV testing.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.